Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated chemoradiotherapy with or without nimorazole in head and neck squamous cell carcinoma using a 15-gene hypoxia signature
2013-002441-12Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nimorazole in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Locoregional control rate. Started Oct 2013; status: completed.
02
Drugs
nimorazole
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2013-002441-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002441-12.